Navigation

New costing templates available

8040872-article-stethoscopeNICE has published new versions of the costing templates for the use of dabigatran etexilate and rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation.

This follows feedback that certain amendments would improve clarity and usefulness of the templates.

The changes to cost impacts are:

  • dabigatran has reduced in national cost cost impact for England from £25.1m to £21.6m (range of £55.4m to a saving of £12.0m).
  • rivaroxaban has reduced in national cost impact for England from £10.2m to £9.9m (range of £39.8 to a saving of £19.9m)

The templates are based on a series of assumptions and for some variables it is hard to obtain absolute estimates. A sensitivity analysis shows this variation and the cost impact is in within ranges. It is important for users to input local data to tailor the templates to obtain more appropriate local cost impacts.

25 October 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.